|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Ortho-McNeil Janssen Scientific Affairs, LLC |
|---|---|
| Collaborator: |
Grünenthal GmbH |
| Information provided by: | Ortho-McNeil Janssen Scientific Affairs, LLC |
| ClinicalTrials.gov Identifier: | NCT00814580 |
Purpose
The purpose of this study is to evaluate how tapentadol Immediate Release (IR) compares with oxycodone Immediate Release (IR) for treating moderate to severe post-operative pain after elective arthroscopic shoulder surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Postoperative Pain |
Drug: Oxycodone IR Drug: Tapentadol IR |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Randomized, Double-Blind, Multi-Center, Parallel-Group Study of Tapentadol Immediate Release (IR) vs. Oxycodone IR for the Treatment of Subjects With Acute Post-operative Pain Following Elective Arthroscopic Shoulder Surgery |
| Estimated Enrollment: | 370 |
| Study Start Date: | December 2008 |
| Estimated Study Completion Date: | January 2010 |
| Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
001: Experimental
Tapentadol IR 50 or 100 mg 4-6 hours PRN; maximum 600 mg a day for 7 days but can be up 9 days
|
Drug: Tapentadol IR
50 or 100 mg 4-6 hours PRN; maximum 600 mg a day for 7 days but can be up 9 days
|
|
002: Active Comparator
Oxycodone IR 5 or 10 mg 4-6 hours PRN; maximum 60 mg a day for 7 days but can be up to 9 days
|
Drug: Oxycodone IR
5 or 10 mg 4-6 hours PRN; maximum 60 mg a day for 7 days but can be up to 9 days
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: | info1@veritasmedicine.com |
Show 41 Study Locations| Study Director: | Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial | Ortho-McNeil Janssen Scientific Affairs, LLC |
More Information
| Responsible Party: | Ortho-McNeil Janssen Scientific Affairs, LLC ( Vice President, Medical Affairs ) |
| Study ID Numbers: | CR015040, Grunenthal protocol KF5503/49, R331333PAI3022 |
| Study First Received: | December 23, 2008 |
| Last Updated: | January 14, 2010 |
| ClinicalTrials.gov Identifier: | NCT00814580 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
analgesia postoperative pain opioid rotator cuff repair labral tear repair |
Bankart procedure oxycodone tapentadol arthroscopic shoulder surgery |
|
Oxycodone Physiological Effects of Drugs Central Nervous System Depressants Pain Narcotics Pharmacologic Actions Signs and Symptoms Pathologic Processes |
Postoperative Complications Sensory System Agents Therapeutic Uses Analgesics Peripheral Nervous System Agents Central Nervous System Agents Analgesics, Opioid Pain, Postoperative |